Burger King considers its new plan of bringing back the Whopper brand to its former glory days, known as "reclaiming the flame," mission-critical for jump-starting its sales in 2022.
The plan focuses on better marketing of the Whopper sandwich, providing fewer coupons for it, and making it easier to assemble the sandwich to get diners in and out of the drive-thru faster.
Restaurant Brands CEO José Cil said they felt it was important to invest behind it and elevate the flagship and iconic product and make sure that it becomes the centerpiece of their game plan going forward.
Cil said that new extensions and innovations around the Whopper, some of which are already proven winners in our international markets, will be tested and expected to perform well in the US.
Burger King's US same-store sales rose 1.8 percent in the fourth quarter, trailing the 7.5 percent gain posted by its arch-rival and Big Mac seller McDonald's.
The Whopper maker registered a 4.7 percent same-store sales increase in the US in 2021.
Burger King's overseas sales have fared better, with a 13.6 percent increase for 2021.


US Eyes Refinery Boost as Trump Seeks Relief From High Gas Prices
Synlait Milk Denies Fonterra, a2 Milk Takeover Talks
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover
Colombia Earthquake Losses Estimated at $9.58 Billion as Reconstruction Challenge Mounts
European Stocks Edge Higher as Fed Rate Pause Bets Rise
Google to Move All Pixel Production Out of China by 2027
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential
Dollar Slides as Soft U.S. Data Cuts Fed Rate Hike Bets
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
NAB Q3 Cash Earnings Rise 2% as Lower Credit Charges Boost Profit
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal
Yen Edges Higher as Weak US Data Dampens Fed Rate Hike Expectations
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 



